Alnylam Pharmaceuticals (NASDAQ:ALNY) CEO Yvonne Greenstreet Sells 8,924 Shares of Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Yvonne Greenstreet sold 8,924 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $4,034,094.20. Following the completion of the sale, the chief executive officer owned 65,409 shares of the company’s stock, valued at $29,568,138.45. This trade represents a 12.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Yvonne Greenstreet also recently made the following trade(s):

• On Monday, August 18th, Yvonne Greenstreet sold 6,979 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $453.27, for a total value of $3,163,371.33.

Alnylam Pharmaceuticals Stock Down 1.0%

ALNY opened at $456.35 on Friday. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The stock has a market capitalization of $59.82 billion, a price-to-earnings ratio of -184.76 and a beta of 0.36. The business has a 50-day moving average of $441.57 and a two-hundred day moving average of $338.75. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $484.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business had revenue of $773.69 million during the quarter, compared to analysts’ expectations of $633.54 million. During the same quarter in the previous year, the business earned ($0.13) EPS. The company’s revenue for the quarter was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on ALNY shares. Wolfe Research upgraded Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a report on Monday, August 4th. Jefferies Financial Group boosted their target price on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a “buy” rating in a report on Monday, July 7th. Royal Bank Of Canada boosted their target price on Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an “outperform” rating in a report on Friday, September 19th. Truist Financial started coverage on Alnylam Pharmaceuticals in a report on Monday, July 21st. They set a “buy” rating and a $385.00 target price for the company. Finally, Evercore ISI boosted their target price on Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an “outperform” rating in a report on Thursday, September 11th. Twenty-four investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $439.58.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. SVB Wealth LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 1st quarter valued at approximately $27,000. Whipplewood Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals by 208.8% during the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 71 shares during the last quarter. Bessemer Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 69 shares during the last quarter. Atlantic Union Bankshares Corp purchased a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $30,000. Finally, Elevation Point Wealth Partners LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $37,000. 92.97% of the stock is owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.